Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902989 | 0.97 | ACHE (0.46) | ACHEGAAKDM4EKMT2ANPC1 | |
| SCHEMBL7910240 | 0.82 | ACHE (0.44) | ACHEGAAKDM4EKMT2ANPC1 | |
| SCHEMBL7910243 | 0.82 | ACHE (0.44) | ACHEGAAKDM4EKMT2ANPC1 | |
| SCHEMBL7910321 | 0.81 | ACHE (0.43) | ACHEGAAKDM4EKMT2ANPC1 | |
| SCHEMBL7910323 | 0.81 | ACHE (0.43) | ACHEGAAKDM4EKMT2ANPC1 | |
| SCHEMBL8143615 | 0.81 | ALDH1A1 (0.44) | KDM4EKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL12797321 | 0.78 | ACHE (0.41) | ACHEGAAKDM4EKMT2ANPC1 | |
| SCHEMBL883087 | 0.77 | MAPT (0.36) | GAAKDM4EKMT2ANPC1RAB9A | |
| SCHEMBL927885 | 0.77 | SLC9A1 (0.60) | ACHEGAAKDM4EKMT2ANPC1 | |
| SCHEMBL10286580 | 0.76 | ALDH1A1 (0.44) | GAAKDM4EKMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013139822-A1 | NOVEL BISOXIME MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| EP-2641901-A1 | Novel microbiocides | Syngenta Participations AG. (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013092460-A1 | CYCLIC BISOXIME MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| US-6258829-B1 | ANTIARRTHMIA AGENTS AND CARDIOVASCULAR DISORDERS | TOA EIYO LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| EP-0972767-A1 | CYCLOALKA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS CONTAINING THE SAME | TOA EIYO LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | ACHE 2246/4885GAA 1211/4885KDM4E 3618/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | ACHE 660/4885GAA 1273/4885KDM4E 1075/4885 |
| US-20140162980-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | PRDX4, PRDX6, DDT | ACHE 736/4885GAA 1279/4885KDM4E 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.